Achillion Pharmaceuticals Inc (ACHN.O)
19 Dec 2014
|Market Cap (Mil.):||$1,424.51|
|Shares Outstanding (Mil.):||100.25|
- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent.
(Adds details, analysts' comments on data, share movement)
Aug 15 - Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.
|Pfizer Inc. (PFE.N)||$31.94||-0.03|
|Johnson & Johnson (JNJ.N)||$105.55||-1.26|
|Novartis AG (NOVN.VX)||CHF93.05||+0.95|
|Merck & Co., Inc. (MRK.N)||$59.58||+0.60|
|Roche Holding Ltd. (ROG.VX)||CHF270.40||-18.30|
|Abbott Laboratories (ABT.N)||$46.05||+0.28|
|AstraZeneca plc (AZN.L)||4,565.00p||-7.50|
|GlaxoSmithKline plc (GSK.L)||1,392.00p||+13.50|
|Bristol-Myers Squibb Co (BMY.N)||$61.30||+0.51|
|Bristol-Myers Squibb Co (BMYMP.PK)||$980.15||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ACHILLION PHARMACEUTICALS including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: Wright Reports
"The Economy Matters" Report for ACHN: the economy's impact on ACHN's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.